Comparing Total Mesorectal Excision With and Without Lateral Lymph Node Dissection
for Lower Rectal Cancer with Suspected Lymph Node Spread
Led by Sixth Affiliated Hospital, Sun Yat-sen University · Updated on 2022-11-25
250
Participants Needed
1
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial investigates treatment methods for low rectal cancer in patients with regional lymph node metastasis, comparing Japanese and Western approaches. Japanese guidelines recommend total mesorectal excision TME combined with lateral lymph node dissection LLND, while Western guidelines favor TME alone after neoadjuvant chemo-radiotherapy nCRT. The study aims to provide high-level clinical evidence on the efficacy and safety of these two strategies for suspected local lymph node metastasis in low rectal cancer.
Participants will be randomly assigned to one of two groups one group will undergo TME with LLND surgery, and the other will receive nCRT followed by TME surgery. The study compares these two procedures directly to understand their impact on disease control and side effects.
During the trial, participants will be monitored for outcomes including 3-year disease-free survival, overall survival, local recurrence rates, and post-surgery complications such as sexual, urinary, and defecation dysfunction. Researchers will also assess operative time, blood loss, postoperative complications, and quality of life at specific intervals up to five years after surgery. The study involves regular evaluations after the operation to track progress and safety.
CONDITIONS
Brief Title
Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy
Research Team
Y
Yanxin Luo
S
Shaoyong Peng
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologically confirmed adenocarcinoma located below the peritoneal reflection, clinical stage II
Tumor suitable for radical resection
No previous chemotherapy or pelvic radiation for any cancer
Written informed consent provided
Lower tumor margin confirmed below the peritoneal reflection
Clinical stage T1-3 N1-2 M0 confirmed by multidisciplinary team based on MRI and endorectal ultrasound
You will not qualify if you...
History of other cancers
Multiple primary colorectal cancers or familial adenomatous polyposis
Presence of inflammatory bowel disease
Tumor recurrence or invasion of other organs
Obstruction, perforation, or bleeding requiring emergency surgery
Tumor invasion of external sphincter, levator ani muscle, or adjacent organs
Participation in another clinical trial within 4 weeks
American Society of Anesthesiologists (ASA) score 4 or higher and/or Eastern Cooperative Oncology Group (ECOG) score 2 or higher
Pregnant or lactating patients
Severe infection before surgery
Psychological disorders
Severe organ dysfunction or other contraindications
Cardiac infarction within 6 months
Severe pulmonary emphysema or pulmonary fibrosis
Surgeon’s decision for exclusion
Operative findings showing tumor invasion of other organs or lower tumor margin above the peritoneal reflection
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Neoadjuvant Chemo-radiotherapy
Duration - As per treatment schedule before surgery
Participants in the TME+nCRT group receive new adjuvant chemo-radiotherapy before surgery.
Multiple visits as per chemo-radiotherapy protocol
Surgery
Duration - Operation day
Participants undergo Total Mesorectal Excision (TME), with or without Lateral Lymph Node Dissection (LLND) depending on group assignment.
1 visit (in-person, surgery day)
Post-operative Follow-up
Duration - Up to 3 months after surgery
Participants are monitored for postoperative complications and recovery, including assessments of urinary, sexual, and defecation functions, and quality of life.
Approximately 6 post-operative visits
Long-term Monitoring
Duration - Up to 5 years after surgery
Participants are followed to assess disease-free survival, local recurrence, and overall survival.
Periodic visits over 5 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Posterior Tibial Nerve Stimulation for Improving Fecal Control and Quality of Life After Rectal Cancer Surgery
Using Metabolomic Profiles to Predict How Locally Advanced Rectal Cancer Responds to Total Neoadjuvant Therapy and Its Side Effects
Comparing Total Mesorectal Excision With and Without Lateral Lymph Node Dissection
for Lower Rectal Cancer with Suspected Lymph Node Spread
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial.
Erectile and urinary function in men with rectal cancer treated by neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy alone: a randomized trial report.
Urinary dysfunction after rectal cancer surgery: Results from a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for clinical stage II or III lower rectal cancer (Japan Clinical Oncology Group Study, JCOG0212).
Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy.
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.